March 1, 2021 7:36am
The CDC and Prevention advisory panel voted unanimously Sunday to recommend the use of Johnson & Johnson’s (JNJ) one-shot Covid-19 vaccine for people 18 years of age and older. The company expects to ship out 4 million of doses initially.
Earnings’ releases: Precigen (PGEN), Adverum Biotechnologies (ADVM) and Regenxbio (RGNX)
Pre-open in 6 BUY and 4 SELLs
Companies mentioned: AGTC, BLUE, BSTG, CRSP, VYGR, EDIT, MESO, NTLA, PGEN
What I provide is a trusted source of share pricing intelligence that ensures that investors are kept apprised of “our” universe, the RegMed/cell and gene therapy sector and its surrounding markets
Dow futures are UP +0.94% (+290 points), S&P futures are UP +1.02% (+39 points) and NASDAQ futures are UP +1.24% (+161 points)
U.S. stock futures surged in early morning trading on Monday, as Treasury yields continued to dip to 1.4358%, retreating from their highs of last week,
European stocks rose sharply with the pan-European Stoxx 600 jumping +1.6% by mid-morning,
Asia-Pacific stocks traded higher despite data releases showing China’s manufacturing activity growth slowing in February. China’s official manufacturing Purchasing Managers’ Index (PMI) for February came in at a lower 50.6 over the weekend.
Data Docket: Markit’s U.S. manufacturing purchasing managers’ index for February comes out on Monday at 9:45 a.m. ET. Economists are expecting a read of 58.5, the same as December’s read of 58.5.
Henry’omics:
Last week and month bounced to some bottoms during “our” universe earnings’ season …
The Dow swung wildly Friday to close near its session struggling to shake off fears of rapidly rising rates, the S&P 500 slid 2.5% this week for its second negative week in a row; while the Nasdaq was lost -4.9%
For the month of February, the Dow gained 3.15%, the S&P 500 gained 2.61% and the Nasdaq gained nearly 1%.
Coming attractions: earnings’ releases – Monday - Precigen (PGEN), Adverum Biotechnologies (ADVM) and Regenxbio (RGNX); Thursday, 3/4 – Cellectis SA (CLLS)
Friday’s evening’s recap: “telling a sector story with daily data; I am able to walk the talk of data and science to provide better sector investment, updates and review” … https://www.regmedinvestors.com/articles/11789
- The Nasdaq closed UP +72.91 points (+0.56%);
- The IBB closed down -0.14% and XBI closed up +0.76%;
- Sector volume was LOW with 6 of the 18-upside having higher than the 3-month average volume with the increased volume of 5 of 15-downside having higher than the 3-month average volume;
- The CBOE Volatility Index (VVIX: INDEX) was down -0.94 points or -3.25% at 27.95
- Friday’s percentage (%) of the 18-upside were +0.48% (PSTI) to +10.60% (BLUE) while the 15-downside ranges from -0.42% (VSTM) to -8.99% (VYGR);
Q1/2021:
March: beginning today
February: 9 positive, 10 negative closes and 1 holiday
January: 10 positive, 9 negative closes and 1 holiday
Companies in my headlights – It’s your decision; I provide an idea and context:
Maintaining Sell: Questions continue …
Biostage (BSTG) closed down again -$0.15 to $1.65 with 959 shares traded, after Thursday’s -$0.00 to $1.80 with 3310 shares traded, Wednesday’s -$0.00 with 0 shares traded, Tuesday’s -$0.20 to $1.80 with 4,062 shares traded and last Monday’s +$0.145 to $2.00 with 2,094 shares traded. Reiterating …
Question#1: WHERE is all the money from DST Capital going or even coming FROM – “to pump the public share price”? just think over the past months if those dollars were put into the company coffers, they wouldn’t be cutting back on employees’ salaries – also WHAT did they take PPP funds for or MAYBE a clinical trial would have been initiated?
Question#2: WHAT is the relationship of DST Capital beyond being BSTG’s investor as they are BOTH based in the same offices – together. WHY is Dixintong Technology Group in Beijing, China led by Donghai Lui defining BSTG’s path forward as Hong Yu, BSTG’s president reports to him through Jason Chen, BSTG’s chairman who also reports to Beijing while managing DST Capital, bottom-line his wife’s (Mrs. bin Zhao) money?
Question#3: WHY are there NO answers from BSTG and some reasons to resolve all these accusations? NO finance professionals employed by company (so far) – HOW can RSM US LLP facilitate their AUDIT of financial and operational controls?
BUY:
Applied Genetic Technologies (AGTC) closed down -$0.22 to $5.08 after Thursday’s $5.30, Wednesday’s $5.65, Tuesday’s $5.41 and last Monday’s $6.24 with a positive +$0.32 or +6.30% pre-market indication;
bluebird bio (BLUE) closed up +$2.98 to $31.10 after Thursday’s $28.12, Wednesday’s $25.92, Tuesday’s $25.62 and last Monday’s $26.07 with a positive +$0.40 or +1.29% aftermarket indication;
CRISPR Therapeutics (CRSP) closed down again -$1.59 to $125.69 after Thursday’s -$6.24 to $127.28, Wednesday’s -$1.78 to $133.52, Tuesday’s -$3.26 to $135.30 and last Monday’s $138.56 with a positive +$4.31 or +3.43% pre-market indication.
Editas Medicine (EDIT) closed down -$0.90 to $43.86 after Thursday’s -$4.94 to $44.76, Wednesday’s +$0.56 to $49.70, Tuesday’s $49.14, Monday’s $52.52 with a positive +$1.14 or +2.60% pe-market indication. Earnings’ release was last Thursday …
Intellia Therapeutics (NTLA) closed up +$2.99 to $60.46 after Thursday’s -$6.25 to $57.47, Wednesday’s +$0.15 to $63.72, Tuesday’s -$2.59 to $63.57, Monday’s $66.16 with a positive +$0.54 or +0.89% pre-market indication. Earnings’ release was Thursday …
Voyager Therapeutics (VYGR) closed down -$0.56 to $5.67 after Thursday’s $6.23, Wednesday’s $6.59, Tuesday’s $6.47 and last Monday’s $6.68 with a positive +$0.13 or +2.29% pre-market indication;
SELL:
Global Blood Therapeutics (GBT) closed down -$0.90 to $42.60 after Thursday’s $43.50, Wednesday’s $49.19, Tuesday’s $48.03 and last Monday’s $48.47 with a negative -$1.49 or -3.50% aftermarket indication;
Mesoblast (MESO) closed flat at $9.60 after Thursday’s $9.60, Wednesday’s $9.53, Tuesday’s $10.11 and last Monday’s $10.26 with a negative -$0.50 or -5.21% aftermarket indication;
Precigen (PGEN) closed up +$0.15 to $8.44 after Thursday’s $8.29, Wednesday’s $8.57, Tuesday’s $8.27 and last Monday’s $8.22 with a negative -$0.04 or -0.47% aftermarket indication;
The BOTTOM LINE: The Ides of March has not quite happened yet; the 15th was very unlucky for one man a very long time ago – let’s NOT it be ours.
On that date in the year 44 BC Julius Caesar was killed. March 15 may not be unlucky for you but it was for Julius Caesar.
I am a “beware Man” whose focus has always been “warning analysis” … earnings’ season is NOT over … my advice, trim and skim … if one can!”
If you want to BUY, consider those who have “reported” earnings … it’s STILL all about, the “bouncing ball” of sector momentum.
Many talk of horizons; “as I have said last week, my horizon is usually a Friday’s close …”
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.
Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
